+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advanced cervical cancer therapy: concurrent radiation therapy and cisplatin chemotherapy for advanced cervical cancer--a toxicity report



Advanced cervical cancer therapy: concurrent radiation therapy and cisplatin chemotherapy for advanced cervical cancer--a toxicity report



American Journal of Clinical Oncology 12(6): 461-466



It is estimated that in 1988 there will be 12,900 cancers of the uterine cervix, representing 2.6% of cancers in women. Radiation therapy has been the primary mode of therapy/palliation; for the past 15-20 years survival results achieved with radiotherapy have plateaued. Attempts have been made to find agents to use with radiation aimed at decreasing recurrence and increasing survival. Phase II studies suggest cisplatin may be an excellent agent to combine with radiotherapy. This study was performed to evaluate the toxicity of this combination. Between December 10, 1980, and August 29, 1986, nine patients with advanced cervical cancer and poor prognosis and one patient with recurrent disease were enrolled. The Gynecologic Oncology Group (GOG) criteria for adverse effects were used in this study. Hematologic, gastrointestinal, genitourinary, and skin parameters were examined. Most adverse criteria had a score of 2 or less. Grade 2 nausea/vomiting was the most frequent problem. Anemia was the next most frequent and was the most serious problem encountered. Overall, the toxicity was acceptable; therefore it seems appropriate to proceed to larger studies to evaluate efficacy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039195414

Download citation: RISBibTeXText

PMID: 2589227


Related references

Pelvic radiation with concurrent chemotherapy compared with pelvi and para-aortic radiation for high-risk cervical cancer. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. Cancer Radiotherapie 3(4): 345-347, 1999

The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer. European Review for Medical and Pharmacological Sciences 18(22): 3491-3496, 2014

A preliminary report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecologic Oncology 42(2): 178-181, 1991

Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival. European Journal of Gynaecological Oncology 31(1): 18-22, 2010

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecologic Oncology 125(1): 158-162, 2012

Adjuvant Pelvic Intensity Modulated Radiation Therapy and Concurrent Docetaxel and Cisplatin Chemotherapy for Postoperative Cervical Cancer With Adverse Risk Factors: A Retrospective Report on Toxicity and Outcomes. International Journal of Radiation Oncology*biology*physics 87(2): S403-S404, 2013

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecologic Oncology 112(1): 85-89, 2009

Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecologic Oncology 122(1): 9, 2011

Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World Journal of Gastroenterology 12(34): 5501-5508, 2006

Randomized prospective trial of extended field radiation therapy versus pelvic radiation therapy alone and with chemotherapy for advanced cervical cancer Preliminary report. International Journal of Radiation Oncology Biology Physics 39(2 Suppl. ): 299, 1997

A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology 70(1): 19-24, 2006

The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. Journal of the Formosan Medical Association 114(3): 231-237, 2015

Phase I trial of nelfinavir added to cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Gynecologic Oncology 154: 267-268, 2019

Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience. Medicine 96(10): E6158, 2017

Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Preliminary report. Journal of Clinical Oncology 24(18_Suppl): 7101-7101, 2016